RareFinance peopleInnovationCareers PipelineCollaborationAdvance treatment SVGOMG The best SVG optimizer and minifier Open SVG Paste markup Demo Contribute SVGOMG provides you several options to clean and compress your SVG files. Clean up, remove, merge, minify. Upload or copy the source of your SVG to get started! 947 bytes → 267 bytes 28.19% Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

We focus on advancing the science of IgG-modulation to develop innovative immunomodulatory treatments that can address the urgent unmet medical needs of people living with rare immunologic conditions.

Scientific collaborations

Discovering new medicines is something we can’t do alone. Collaborating with scientific and medical experts around the world is critical to advancing cutting-edge science and delivering innovative new medicines. To that end, Hansa collaborates with a number of leading medical, research and academic institutions around the world:

Cedars Sinai logo
Johns Hopkins University logo
NYU Langone Medical Center logo
University of Oxford logo
Necker Hospital University logo
Lund University logo
Uppsala University logo

Out-licensing collaborations

Heparin binding protein assay

Additionally, out-licensing our scientific advancements and methods lends to overall drug discovery and development. Hansa out-licenses the Heparin Binding Protein (HBP) Assay to UK-based Axis-Shield Diagnostics, a subsidiary of Abbott. Hansa Biopharma holds the right to royalty payments from Axis-Shield.

The HBP Assay was originally developed and patented by researchers at Lund University in collaboration with Hansa to assist in predicting severe sepsis in patients with infectious disease symptoms.